Produção Nacional
Revisado por pares
Long-Term Follow-Up of At Least Five Years After Recombinant Human Thyrotropin Compared to Levothyroxine Withdrawal for Thyroid Remnant Ablation with Radioactive Iodine
2012; Mary Ann Liebert, Inc.; Volume: 22; Issue: 3 Linguagem: Inglês
10.1089/thy.2011.0242
ISSN1557-9077
AutoresPedro Weslley Rosário, Augusto Flávio Campos Mineiro Filho, Rafaela Xavier Lacerda, Maria Regina Calsolari,
Tópico(s)Head and Neck Anomalies
ResumoThyroidVol. 22, No. 3 Letters to the EditorLong-Term Follow-Up of At Least Five Years After Recombinant Human Thyrotropin Compared to Levothyroxine Withdrawal for Thyroid Remnant Ablation with Radioactive IodinePedro Weslley Rosario, Augusto Flávio Campos Mineiro Filho, Rafaela Xavier Lacerda, and Maria Regina CalsolariPedro Weslley RosarioPostgraduate Center, Santa Casa de Belo Horizonte, Belo Horizonte, Brazil.Endocrinology Service, Santa Casa de Belo Horizonte, Belo Horizonte, Brazil.Search for more papers by this author, Augusto Flávio Campos Mineiro FilhoPostgraduate Center, Santa Casa de Belo Horizonte, Belo Horizonte, Brazil.Search for more papers by this author, Rafaela Xavier LacerdaPostgraduate Center, Santa Casa de Belo Horizonte, Belo Horizonte, Brazil.Search for more papers by this author, and Maria Regina CalsolariEndocrinology Service, Santa Casa de Belo Horizonte, Belo Horizonte, Brazil.Search for more papers by this authorPublished Online:1 Mar 2012https://doi.org/10.1089/thy.2011.0242AboutSectionsView articleView Full TextSupplemental MaterialPDF/EPUBView Supplemental Data Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"Long-Term Follow-Up of At Least Five Years After Recombinant Human Thyrotropin Compared to Levothyroxine Withdrawal for Thyroid Remnant Ablation with Radioactive Iodine." , 22(3), pp. 332–333FiguresReferencesRelatedDetailsCited byRecombinant Thyrotropin vs Levothyroxine Withdrawal in 131I Therapy of N1 Thyroid Cancer: A Large Matched Cohort Study (ThyrNod)5 November 2018 | The Journal of Clinical Endocrinology & Metabolism, Vol. 104, No. 42015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer Bryan R. Haugen, Erik K. Alexander, Keith C. Bible, Gerard M. Doherty, Susan J. Mandel, Yuri E. Nikiforov, Furio Pacini, Gregory W. Randolph, Anna M. Sawka, Martin Schlumberger, Kathryn G. Schuff, Steven I. Sherman, Julie Ann Sosa, David L. Steward, R. Michael Tuttle, and Leonard Wartofsky12 January 2016 | Thyroid, Vol. 26, No. 1Recombinant Human Thyroid Stimulating Hormone versus Thyroid Hormone Withdrawal for Radioactive Iodine Treatment of Differentiated Thyroid Cancer with Nodal Metastatic DiseaseJournal of Oncology, Vol. 2016ATA Guideline in a View Point of Nuclear MedicineInternational Journal of Thyroidology, Vol. 8, No. 2The Evolving Use of Radioiodine Therapy in Differentiated Thyroid Cancer11 December 2014 | Oncology, Vol. 88, No. 4Controversy Over Radioiodine Ablation In Thyroid CancerSurgical Clinics of North America, Vol. 94, No. 3Stimulated Thyroglobulin at Recombinant Human TSH-Aided Ablation Predicts Disease-free Status One Year LaterThe Journal of Clinical Endocrinology & Metabolism, Vol. 98, No. 11Patients With Differentiated Thyroid Cancer Who Underwent Radioiodine Thyroid Remnant Ablation With Low-Activity 131I After Either Recombinant Human TSH or Thyroid Hormone Therapy Withdrawal Showed the Same Outcome After a 10-Year Follow-upThe Journal of Clinical Endocrinology & Metabolism, Vol. 98, No. 7Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensusArquivos Brasileiros de Endocrinologia & Metabologia, Vol. 57, No. 4Recombinant Human Thyroid-Stimulating Hormone To Stimulate 131-1 Uptake For Remnant Ablation And Adjuvant TherapyEndocrine Practice, Vol. 19, No. 1Radioiodine treatment of well-differentiated thyroid cancer26 June 2012 | Endocrine, Vol. 42, No. 3Recombinant Human Thyroid Stimulating Hormone–Assisted Radioactive Iodine Remnant Ablation in Thyroid Cancer Patients at Intermediate to High Risk of Recurrence Jonathan Hugo, Eyal Robenshtok, Ravinder Grewal, Steve Larson, and R. Michael Tuttle1 October 2012 | Thyroid, Vol. 22, No. 10 Volume 22Issue 3Mar 2012 InformationCopyright 2012, Mary Ann Liebert, Inc.To cite this article:Pedro Weslley Rosario, Augusto Flávio Campos Mineiro Filho, Rafaela Xavier Lacerda, and Maria Regina Calsolari.Long-Term Follow-Up of At Least Five Years After Recombinant Human Thyrotropin Compared to Levothyroxine Withdrawal for Thyroid Remnant Ablation with Radioactive Iodine.Thyroid.Mar 2012.332-333.http://doi.org/10.1089/thy.2011.0242Published in Volume: 22 Issue 3: March 1, 2012Online Ahead of Print:January 10, 2012PDF download
Referência(s)